Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etanercept + methotrexate
- Development stage
- Phase 4
- Lead developer
- Amgen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral, Intramuscular, Intravenous
01
Overview
Etanercept + methotrexate is a combination therapy used primarily for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions. Etanercept is a biologic fusion protein that acts as a tumor necrosis factor (TNF) blocker by binding specifically to TNF and inhibiting its activity, thereby reducing inflammation and immune-mediated tissue damage[1][4][5]. Methotrexate is a disease-modifying antirheumatic drug (DMARD) that inhibits enzymes involved in nucleotide synthesis, leading to anti-inflammatory effects by preventing cell division in rapidly proliferating cells such as those involved in the immune response[6]. The combination of these two drugs provides enhanced efficacy compared to either agent alone for many patients with moderate-to-severe rheumatoid arthritis and related conditions[4].
- Brand names
- Enbrel (etanercept)Trexall (methotrexate)Rheumatrex (methotrexate)
- Other names
- MTX + ETNMTX + Enbrel
02
Targets
DHFR (Dihydrofolate reductase)TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)
Beyond the preview
Go deeper on etanercept + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etanercept + methotrexate.